Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vipidia

Sanofi reception

Sanofi gets EU OK for Ablynx flagship drug Cablivi

EMA clears the drug to treat adults with aTTP

- PMLiVE

Novartis wins key adjuvant Taf/Mek approval in Europe

Ex-GSK duo on course for first blockbuster year

- PMLiVE

Novartis and Gilead rival CAR-Ts approved in Europe, but supply capacity in question

Gilead looks to have edge in crucial manufacturing capability

- PMLiVE

Novartis considers filings for PI3K drug in breast cancer

Those treated with alpelisib had longer PFS than those on fulvestrant alone

AstraZeneca AZ

AZ rival to GSK’s COPD drug Anoro fails head-to-head test

Its combo missed two of the main endpoints of the study

The European Medicines Agency: PRIME’d for access?

Leela Barham examines the impact of the EMA's PRIME fast track system after two years

- PMLiVE

The race for a HIV ‘cure’

Supercharging therapies as pharma and patients work together

- PMLiVE

After Cohen payment scandal, Novartis unveils new ethics chief

New 'risk and compliance' leader has increased powers

- PMLiVE

FDA gives breakthrough status to Xolair for food allergies

Food allergies could open up big new market for biologic

- PMLiVE

EMA cuts back as Brexit staff losses top expectations

Regulator says it faces loss of 30% of staff

- PMLiVE

Daily Brief: European approvals for BMS’ Opdivo, Aegerion’s lipodystrophy treatment, Pfizer’s biosimilar and Xeljanz

Will Pfizer spark price war with its Herceptin biosimilar?

- PMLiVE

Immunology keeps Shire figures solid as Takeda takeover nears

Shire’s sales increased by 6% to $3.81bn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links